AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) saw unusually-high trading volume on Thursday . Approximately 361,343 shares changed hands during trading, a decline of 58% from the previous session’s volume of 853,144 shares.The stock last traded at $3.47 and had previously closed at $3.60.

ACRX has been the subject of a number of research reports. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Oppenheimer reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, August 3rd. Cantor Fitzgerald set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 1st. LADENBURG THALM/SH SH started coverage on shares of AcelRx Pharmaceuticals in a report on Thursday, August 16th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 7th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $5.25.

The company has a current ratio of 4.01, a quick ratio of 3.96 and a debt-to-equity ratio of -0.15. The firm has a market capitalization of $233.31 million, a P/E ratio of -3.62 and a beta of 2.04.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.93 million. As a group, research analysts expect that AcelRx Pharmaceuticals Inc will post -0.83 earnings per share for the current year.

In other news, CEO Vincent J. Angotti acquired 10,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were purchased at an average price of $2.90 per share, for a total transaction of $29,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lawrence G. Hamel sold 6,953 shares of the business’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $4.50, for a total transaction of $31,288.50. Following the completion of the transaction, the insider now owns 24,371 shares in the company, valued at approximately $109,669.50. The disclosure for this sale can be found here. Insiders acquired a total of 57,300 shares of company stock worth $159,552 in the last quarter. 25.50% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of ACRX. GSA Capital Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals in the 1st quarter valued at about $113,000. Lincoln Capital Corp acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at about $116,000. Granite Investment Partners LLC acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at about $182,000. Northern Trust Corp raised its stake in shares of AcelRx Pharmaceuticals by 60.8% in the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares in the last quarter. Finally, FMR LLC raised its stake in shares of AcelRx Pharmaceuticals by 1,094.6% in the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 273,644 shares in the last quarter. Institutional investors and hedge funds own 8.57% of the company’s stock.

AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Further Reading: Are analyst ratings accurate?

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.